Anna-Maria Globig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anna-Maria Globig has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Susan M. Kaech
Salk Institute for Biological Studies, La Jolla, CA
46 shared publications - Alexandra Kuhlmann-Hogan
NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, California
44 shared publications - Camila Robles-Oteíza
Yale School of Medicine 1 Department of Immunobiology New Haven, CT
44 shared publications - Christian M. Metallo
Salk Institute for Biological Studies, La Jolla, CA, USA
44 shared publications - Deborah Ayeni
Departments of Pathology and Internal Medicine (Section of Medical Oncology), Yale School of Medicine, New Haven, Connecticut
44 shared publications - Elizabeth M. Kwong
Sanford Burnham Prebys Medical Discovery Institute, La Jolla, USA
44 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 10 (S4)
The Neuroimmune Connectome: Understanding how the Peripheral Nervous System shapes Immunity
Nerves are active regulators of immunity. Here, we review the current understanding of neuroimmune communication, focusing on how peripheral neurons instruct immune cell differentiation and function. We discuss mechanisms by which neurotransmitters, neuropeptides, and cytokines mediate reciprocal signaling between nerves and immune cells across infection, allergy, autoimmunity, and cancer. We introduce the concept of nerves as “state-setters” of immunity and summarize emerging therapeutic strategies that target neuroimmune pathways. Finally, we highlight current methodological challenges and outline priorities for mapping the peripheral neuroimmune connectome to accelerate clinical translation.
- 22 April 2026
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 10 (S4)
Open AccessThe Neuroimmune Connectome: Understanding how the Peripheral Nervous System shapes Immunity
Nerves are active regulators of immunity. Here, we review the current understanding of neuroimmune communication, focusing on how peripheral neurons instruct immune cell differentiation and function. We discuss mechanisms by which neurotransmitters, neuropeptides, and cytokines mediate reciprocal signaling between nerves and immune cells across infection, allergy, autoimmunity, and cancer. We introduce the concept of nerves as “state-setters” of immunity and summarize emerging therapeutic strategies that target neuroimmune pathways. Finally, we highlight current methodological challenges and outline priorities for mapping the peripheral neuroimmune connectome to accelerate clinical translation.
- Top Cited Papers
- 7 January 2026
- Published by Springer Nature in Nature
- Vol. 651 (8105) , 440-450
Neuro-epithelial circuits promote sensory convergence and intestinal immunity
Type 2 inflammation at barrier surfaces is an evolutionarily conserved response that promotes immunity to helminth parasites, allergic inflammation and tissue repair1,2,3,4. Direct sensing of environmental triggers by epithelial cells initiates type 2 inflammation, and signals derived from neurons can modulate immune responses5,6,7,8. However, how diverse sensory inputs from epithelial, neuronal and immune cells are coordinated and integrated remains unclear. Here we identify that TRPV1+ pain-sensing nociceptors co-opt chemosensory epithelial tuft cells to initiate a cascade of tissue responses that drive type 2 inflammation. Chemogenetic silencing or chemical ablation of TRPV1+ nociceptors results in a significant reduction in intestinal tuft cells and defective anti-helminth type 2 immunity. By contrast, chemogenetic activation of TRPV1+ nociceptors leads to remodelling of CGRP+ nerve fibres, significantly increased CGRP expression, enhanced tuft cell accumulation and protective anti-helminth type 2 immunity. Using spatial transcriptomic and single-cell RNA sequencing analyses, we reveal that nociceptor activation promotes rapid epithelial progenitor cell proliferation and differentiation. Mechanistically, intestinal epithelial cell-intrinsic and tuft cell-intrinsic expression of CGRP receptor subunits are required for tuft cell responses and type 2 immunity to helminth infection. Together, these results identify sensory convergence of a neuronal–epithelial tuft cell circuit as a critical upstream determinant of type 2 immunity and tissue adaptation.
- 7 January 2026
- Published by Springer Nature in Nature
- Vol. 651 (8105) , 440-450
Top Cited PapersNeuro-epithelial circuits promote sensory convergence and intestinal immunity
Type 2 inflammation at barrier surfaces is an evolutionarily conserved response that promotes immunity to helminth parasites, allergic inflammation and tissue repair1,2,3,4. Direct sensing of environmental triggers by epithelial cells initiates type 2 inflammation, and signals derived from neurons can modulate immune responses5,6,7,8. However, how diverse sensory inputs from epithelial, neuronal and immune cells are coordinated and integrated remains unclear. Here we identify that TRPV1+ pain-sensing nociceptors co-opt chemosensory epithelial tuft cells to initiate a cascade of tissue responses that drive type 2 inflammation. Chemogenetic silencing or chemical ablation of TRPV1+ nociceptors results in a significant reduction in intestinal tuft cells and defective anti-helminth type 2 immunity. By contrast, chemogenetic activation of TRPV1+ nociceptors leads to remodelling of CGRP+ nerve fibres, significantly increased CGRP expression, enhanced tuft cell accumulation and protective anti-helminth type 2 immunity. Using spatial transcriptomic and single-cell RNA sequencing analyses, we reveal that nociceptor activation promotes rapid epithelial progenitor cell proliferation and differentiation. Mechanistically, intestinal epithelial cell-intrinsic and tuft cell-intrinsic expression of CGRP receptor subunits are required for tuft cell responses and type 2 immunity to helminth infection. Together, these results identify sensory convergence of a neuronal–epithelial tuft cell circuit as a critical upstream determinant of type 2 immunity and tissue adaptation.
- 17 September 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (10)
Women in STEM becoming independent: Asking for help creates opportunities for connections and kindness
This year at JEM, we are highlighting women in science by sharing their stories and amplifying their voices. In this Viewpoint, we hear from a cross section of women, across multiple research fields, discussing their science and the process of setting up a lab as an independent researcher.
- 17 September 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (10)
Women in STEM becoming independent: Asking for help creates opportunities for connections and kindness
This year at JEM, we are highlighting women in science by sharing their stories and amplifying their voices. In this Viewpoint, we hear from a cross section of women, across multiple research fields, discussing their science and the process of setting up a lab as an independent researcher.
- Open Access
Different signaling interpretations by PKC eta and theta control T cell function and exhaustion
SUMMARY: Chronic antigen signaling drives CD8 + T cell exhaustion (T EX ) in cancer and chronic infection. However, how the kinase cascades downstream of the T cell receptor drive exhaustion is not understood. We found that continuous agonism of protein kinase C (PKC) causes degradation of PKC theta, but not PKC eta, and induces terminal T EX cells. During chronic infection, PKC theta is necessary to maintain the progenitor exhausted (T EX-PROG ) cells, and thus the antigen-specific T cell response, while agonism of PKC eta promotes terminal exhaustion (T EX-TERM ) in vitro and in vivo . The cascades downstream of these kinases are distinct, with PKC theta promoting activity of canonical PKC targets in the MAPK and CDK families, while eta promotes activity of other targets, including casein kinase I G2 (CK1G2). Expression of an engineered, degradation-resistant PKC theta, or deletion of the gene encoding CK1G2, improves T cell function and tumor control. Our illustration of multiple therapeutic avenues arising from targeting PKC highlights its centrality in T EX differentiation and its clinical potential in cancer immunotherapy. Highlights: PKC theta sustains T cell function while PKC eta promotes terminal exhaustion PKC theta and eta drive distinct phospho-cascades to oppose each other’s differentiation instructions An engineered, degradation-resistant PKC theta improves T cell responses in chronic infection and cancer Ablation of kinase CK1G2 downstream of PKC eta improves anti-tumor T cell responses
Open AccessDifferent signaling interpretations by PKC eta and theta control T cell function and exhaustion
SUMMARY: Chronic antigen signaling drives CD8 + T cell exhaustion (T EX ) in cancer and chronic infection. However, how the kinase cascades downstream of the T cell receptor drive exhaustion is not understood. We found that continuous agonism of protein kinase C (PKC) causes degradation of PKC theta, but not PKC eta, and induces terminal T EX cells. During chronic infection, PKC theta is necessary to maintain the progenitor exhausted (T EX-PROG ) cells, and thus the antigen-specific T cell response, while agonism of PKC eta promotes terminal exhaustion (T EX-TERM ) in vitro and in vivo . The cascades downstream of these kinases are distinct, with PKC theta promoting activity of canonical PKC targets in the MAPK and CDK families, while eta promotes activity of other targets, including casein kinase I G2 (CK1G2). Expression of an engineered, degradation-resistant PKC theta, or deletion of the gene encoding CK1G2, improves T cell function and tumor control. Our illustration of multiple therapeutic avenues arising from targeting PKC highlights its centrality in T EX differentiation and its clinical potential in cancer immunotherapy. Highlights: PKC theta sustains T cell function while PKC eta promotes terminal exhaustion PKC theta and eta drive distinct phospho-cascades to oppose each other’s differentiation instructions An engineered, degradation-resistant PKC theta improves T cell responses in chronic infection and cancer Ablation of kinase CK1G2 downstream of PKC eta improves anti-tumor T cell responses
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S1: Myeloid cell regulation during lung tumorigenesis.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S1: Myeloid cell regulation during lung tumorigenesis.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S6: Single cell analysis of tumorigenesis in humans reveals rewired LUAD patient macrophage lipid and mitochondrial metabolism.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S6: Single cell analysis of tumorigenesis in humans reveals rewired LUAD patient macrophage lipid and mitochondrial metabolism.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S5: PPARγ Antagonist GW9662 modulates induces tumor regression and modulates the TME.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S5: PPARγ Antagonist GW9662 modulates induces tumor regression and modulates the TME.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S5: PPARγ Antagonist GW9662 modulates induces tumor regression and modulates the TME.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S5: PPARγ Antagonist GW9662 modulates induces tumor regression and modulates the TME.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S2: Innate immune cells are regulated by GM-CSF and contributes to tumorigenesis.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S2: Innate immune cells are regulated by GM-CSF and contributes to tumorigenesis.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S4: Deficiency of PPARγ in CSF1R- or CD11c-expressing cells suppresses tumor growth.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S4: Deficiency of PPARγ in CSF1R- or CD11c-expressing cells suppresses tumor growth.